Key factors
symKTRA
exchUS
MCap3630.52K
Beta0.589
EPS-5.22
Div date0000-00-00
Yesterday
symKTRA
exchUS
close0.104
50 Day MA0.112
200 Day MA2.134
52 Week High5.98
52 Week Low0.081
Target Price 14.0
Market Cap Mln3.630
Share statistics
Shares Outstanding39.03M
Shares Float39.02M
Percent Institutions0.62
PercentInsiders0.208
SharesShort2191.68K
Short Ratio0.18
Shares Short Prior Month411.08K
Short Percent5.620
EBITDA-10.5M
Diluted Eps TTM-5.22
earning
EPS Estimate Current Year -0.46
EPS Estimate Next Year -0.38
Earnings Share -5.22
Dividend
Dividend Date2019-05-08
Last Split Date 2022-11-14
Last Split Factor1:50
business
Enterprise Value Ebitda -1.23
Book Value /share -1.02
Price Book MRQ 7.807
ReturnOnAssetsTTM -1.12
ReturnOnEquityTTM-3.29
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic Sector Health Care
Gic Sub Industry Biotechnology
IndustryBiotechnology
SectorHealthcare
ISIN US49720K1016
CIK 1498382
Code KTRA
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2024-03-22
Fiscal Year End June
Full Time Employees2.0
IPODate 2013-02-22
MostRecent Quarter2023-12-31
Contact
NameKintara Therapeutics Inc
Address9920 Pacific Heights Blvd, San Diego, CA, United States, 92121
Country NameUSA
Phone858 350 4364
Web URLhttps://www.kintara.com
Logo URL/img/logos/US/KTRA.png
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.